COMMISSION IMPLEMENTING DECISION (EU) 2026/381

| Official Journal of the European Union | EN L series ---|---|--- * * * | 2026/381 | 23.2.2026 ---|---|--- COMMISSION IMPLEMENTING DECISION (EU) 2026/381 of 20 February 2026 postponing the expiry date of the approval of tebuconazole for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (1), and in particular Article 14(5) thereof, After consulting the Standing Committee on Biocidal Products, Whereas: (1) | Tebuconazole was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council (2) as an active substance for use in biocidal products of product-type 8. Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved until 31 March 2020 under that Regulation subject to the conditions set out in Annex I to Directive 98/8/EC. ---|--- (2) | On 27 September 2018, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of tebuconazole for use in biocidal products of product-type 8 (‘the application’). ---|--- (3) | On 6 February 2019, the evaluating competent authority of Denmark informed the Commission that it had decided, pursuant to Article 14(1) of Regulation (EU) No 528/2012, that a full evaluation of the application was necessary. Pursuant to Article 8(1) of that Regulation, the evaluating competent authority is to perform a full evaluation of the application within 365 days of its validation. ---|--- (4) | The evaluating competent authority may, as appropriate, require the applicant to provide sufficient data to carry out the evaluation, in accordance with Article 8(2) of Regulation (EU) No 528/2012. In that event, the 365-day period is suspended for a period that may not exceed 180 days in total unless a longer suspension is justified by the nature of the data requested or by exceptional circumstances. ---|--- (5) | Within 270 days of receipt of a recommendation from the evaluating competent authority, the European Chemicals Agency (‘the Agency’) is to prepare and submit to the Commission an opinion on renewal of the approval of the active substance in accordance with Article 14(3) of Regulation (EU) No 528/2012. ---|--- (6) | Commission Implementing Decision (EU) 2019/1951 (3) postponed the expiry date of the approval of tebuconazole for use in biocidal products of product-type 8 to 30 September 2022, in order to allow sufficient time for the examination of the application. ---|--- (7) | Commission Implementing Decision (EU) 2022/1496 (4) postponed again the expiry date of the approval to 30 June 2026 due to delays in the evaluation of the application. ---|--- (8) | On 29 September 2025, the evaluating competent authority informed the Commission that the evaluation is delayed due to additional time needed by the authority to assess the endocrine-disrupting properties of the substance. ---|--- (9) | Consequently, for reasons beyond the control of the applicant, the approval is likely to expire before a decision has been taken on its renewal. It is therefore appropriate to further postpone the expiry date of the approval for a period of time sufficient to enable the examination of the application. Taking into account the time-limits for evaluation by the evaluating competent authority, for preparation and submission by the Agency of its opinion and the time needed for the Commission to decide whether to renew the approval of tebuconazole for use in biocidal products of product-type 8, the expiry date should be postponed to 30 June 2027. ---|--- (10) | After the further postponement of the expiry date of the approval, tebuconazole remains approved for use in biocidal products of product-type 8 subject to the conditions set out in Annex I to Directive 98/8/EC, ---|--- HAS ADOPTED THIS DECISION: Article 1 The expiry date of the approval of tebuconazole for use in biocidal products of product-type 8 set out in Annex I to Directive 98/8/EC is postponed to 30 June 2027. Article 2 This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. Done at Brussels, 20 February 2026. For the Commission The President Ursula VON DER LEYEN * * * (1) OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj. (2) Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (OJ L 123, 24.4.1998, p. 1, ELI: http://data.europa.eu/eli/dir/1998/8/oj). (3) Commission Implementing Decision (EU) 2019/1951 of 25 November 2019 postponing the expiry date of approval of tebuconazole for use in biocidal products of product-type 8 (OJ L 304, 26.11.2019, p. 21, ELI: http://data.europa.eu/eli/dec_impl/2019/1951/oj). (4) Commission Implementing Decision (EU) 2022/1496 of 8 September 2022 postponing the expiry date of the approval of tebuconazole for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 234, 9.9.2022, p. 28, ELI: http://data.europa.eu/eli/dec_impl/2022/1496/oj). * * * ELI: http://data.europa.eu/eli/dec_impl/2026/381/oj ISSN 1977-0677 (electronic edition) * * *